The potential use of histone deacetylase inhibitors in the treatment of depression

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4:64:320-4. doi: 10.1016/j.pnpbp.2015.03.010. Epub 2015 Mar 25.

Abstract

Numerous preclinical studies demonstrate that changes in gene expression in the brain occur in animal models of depression using exposure to stress, such as social defeat and leaned helplessness, and that repeated administration of antidepressants ameliorates these stress-induced changes in gene expression. These findings suggest that alteration in gene transcription in the central nervous system in response to stress plays an important role in the pathophysiology of depression. Recent advances in epigenetics have led to the realization that chromatin remodeling mediated by histone deacetylase (HDAC) is closely involved in the regulation of gene transcription. In this context, we first review several preclinical studies demonstrating the antidepressant-like efficacy of HDAC inhibitors. We then suggest the efficacy of HDAC inhibitors in treatment-resistant depression based on the mechanism of action of HDAC. Finally, we discuss the possibility of using HDAC inhibitors in patients with treatment-resistant depression.

Keywords: Antidepressant; Brain-derived neurotrophic factor (BDNF); Depression; Histone deacetylase; Histone deacetylase (HDAC) inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antidepressive Agents / pharmacology
  • Antidepressive Agents / therapeutic use*
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / genetics
  • Depressive Disorder / metabolism
  • Gene Expression Regulation / drug effects
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylase Inhibitors / therapeutic use*
  • Humans

Substances

  • Antidepressive Agents
  • Histone Deacetylase Inhibitors